Efficacy of pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms-A bayesian network meta-analysis.

CNS Neuroscience & Therapeutics
Jiande LiYing Peng

Abstract

We aimed to compare and rank the efficacy of different pharmacotherapeutics for patients comorbid with alcohol use disorders and depressive symptoms. Bayesian network meta-analysis was performed for three different outcome parameters: alcohol use disorders (AUD) remission rate, percent abstinent days, and scores of depression scales. The surface under the cumulative ranking curves (SUCRA) was used for ranking the efficacy of interventions. Sensitivity analysis and direct pairwise analysis were conducted to validate the main results. A total of 68 RCTs consisting of 5890 patients were included. Disulfiram could significantly increase the AUD remission rates (OR 5.02, 1.97-12.95) and the percent abstinent days (MD 17.08, 3.48-30.93). Disulfiram was associated with the best efficacy in achieving remission (SUCRA 95.1%) and increasing abstinent days (SUCRA 87.6%). Noradrenaline reuptake inhibitor was significantly more efficacious than controls (SMD -2.44, -3.53 to -1.36) and have the first rank (SUCRA 99.0%) in reducing the scores of depression scales. Antiepileptics have relatively higher ranks in efficacy for both AUD and depressive symptoms. Disulfiram was associated with the best efficacy in achieving abstinence for comorbidit...Continue Reading

References

Jun 1, 1975·The American Journal of Psychiatry·J A ShawJ A Robinson
Dec 1, 1991·Alcoholism, Clinical and Experimental Research·M DongierG Schwartz
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·J G SimeonW Copping
Sep 22, 1989·JAMA : the Journal of the American Medical Association·W DorusU Malkerneker
Mar 1, 1987·Archives of General Psychiatry·J FawcettR D Gibbons
Feb 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·G K ShawG Dunn
May 1, 1984·Journal of Studies on Alcohol·P F GoyerL F Major
Sep 1, 1994·Archives of General Psychiatry·H R KranzlerM J Bohn
Sep 1, 1993·Drug and Alcohol Dependence·E M Krupitsky Borodkin YuS
Jun 1, 1993·The American Journal of Psychiatry·E V NunesK Ocepek-Welikson
Mar 1, 1996·Archives of General Psychiatry·P J McGrathF M Quitkin
Apr 1, 1996·Alcoholism, Clinical and Experimental Research·E MalecM Dongier
Feb 1, 1997·Alcoholism, Clinical and Experimental Research·T I MuellerP R Recupero
Aug 1, 1997·Archives of General Psychiatry·J R CorneliusA Black
Mar 24, 1998·Archives of General Psychiatry·S F GreenfieldJ Michael
Jun 11, 1998·Alcoholism, Clinical and Experimental Research·J BessonA Potgieter
Apr 19, 2000·Journal of Clinical Psychopharmacology·P P Roy-ByrneR K Ries
Jun 1, 2000·Alcoholism, Clinical and Experimental Research·J FawcettG Teas
Aug 3, 2000·Alcoholism, Clinical and Experimental Research·H M PettinatiA Cnaan
Mar 29, 2001·Journal of Clinical Psychopharmacology·H M PettinatiA Cnaan
May 25, 2001·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·M DriessenK Junghanns
Jun 18, 2002·The Medical Journal of Australia·Noeline C LattSonia E Wutzke
Sep 10, 2002·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Giovanni AddoloratoGiovanni Gasbarrini
Feb 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Marisa RobertoGeorge R Siggins
Nov 19, 2003·Journal of Clinical Psychopharmacology·Darlene H MoakRamon Durazo-Arvizu
Nov 25, 2003·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·A GualL Serrano
Apr 16, 2004·Alcoholism, Clinical and Experimental Research·Carlos A Hernandez-AvilaHenry R Kranzler
Apr 27, 2004·Journal of Psychopharmacology·J LiappasG Christodoulou
May 29, 2004·Alcoholism, Clinical and Experimental Research·José GuardiaMiguel Casas
Sep 28, 2004·Statistics in Medicine·G Lu, A E Ades
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·John LiappasAndreas Rabavilas
Mar 17, 2005·Alcoholism, Clinical and Experimental Research·Kathleen T BradyKit Simpson
Jan 18, 2006·Journal of Clinical Psychopharmacology·Henry R KranzlerMartin Keller
Nov 30, 2006·PLoS Medicine·Colin D Mathers, Dejan Loncar
Apr 7, 2007·Journal of Clinical Psychopharmacology·Ismene PetrakisUNKNOWN VA VISN I MIRECC Study Group
Apr 24, 2007·Journal of Anxiety Disorders·Sarah W BookCarrie L Randall
Aug 21, 2007·Biochemical Pharmacology·Justin T Gass, M Foster Olive
Oct 11, 2007·Statistical Methods in Medical Research·Georgia SalantiJohn P A Ioannidis

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
pharmacotherapies

Software Mentioned

OpenBUGS
R
Stata
Getdata
Review Manager

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.